Xenon Pharmaceuticals Inc. 8-K

What Happened
Xenon Pharmaceuticals Inc. announced on February 27, 2026 that it filed a prospectus supplement with the SEC to register up to $400,000,000 of common shares issuable under its at‑the‑market (ATM) equity offering sales agreement with Jefferies LLC and Stifel, Nicolaus & Company. The prospectus supplement replaces and supersedes the prior prospectus and terminates the prior offering. As of the filing date, Xenon has sold $291,084,564 in shares under the Sales Agreement and the prior prospectus. The registered issuance will be made under Xenon’s automatically effective Form S-3 registration statement (File No. 333-281451) filed August 9, 2024. A legal opinion from Blake, Cassels & Graydon LLP is attached as an exhibit.

Key Details

• Filing date: February 27, 2026 (Form 8-K, Item 8.01).
• Amount to register: $400,000,000 of common shares under the ATM program.
• Amount previously sold: $291,084,564 in shares under the Sales Agreement and prior prospectus.
• Sales agents: Jefferies LLC and Stifel, Nicolaus & Company.
• Registration statement: Form S-3 (File No. 333-281451), filed August 9, 2024.
• Exhibit: Opinion of Blake, Cassels & Graydon LLP regarding legality of the shares.

Why It Matters
This filing gives Xenon a refreshed and expanded registration to sell common shares into the open market via its ATM facility, providing the company with flexibility to raise capital as needed. For investors, continued use of the ATM (already $291.08M sold) can mean future share issuance and potential dilution, while supporting Xenon’s funding needs without a traditional follow-on offering. The filing is procedural and does not disclose any specific share issuance amounts, prices, or planned timing beyond registering the capacity to sell up to $400M.